More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report

AUTOR(ES)

Yuan, J.L., Wang, F.L., Yi, X.M., Qin, W.J., Wu, G.J., Huan, Y., Yang, L.J., Zhang, G., Yu, L., Zhang, Y.T., Qin, R.L., Tian, C.J.

FONTE

Braz J Med Biol Res

DATA DE PUBLICAÇÃO

31/10/2014

RESUMO

Although radical nephrectomy alone is widely accepted as the standard of care in localized treatment for renal cell carcinoma (RCC), it is not sufficient for the treatment of metastatic RCC (mRCC), which invariably leads to an unfavorable outcome despite the use of multiple therapies. Currently, sequential targeted agents are recommended for the management of mRCC, but the optimal drug sequence is still debated. This case was a 57-year-old man with clear-cell mRCC who received multiple therapies following his first operation in 2003 and has survived for over 10 years with a satisfactory quality of life. The treatments given included several surgeries, immunotherapy, and sequentially administered sorafenib, sunitinib, and everolimus regimens. In the course of mRCC treatment, well-planned surgeries, effective sequential targeted therapies and close follow-up are all of great importance for optimal management and a satisfactory outcome.

Documentos Relacionados

• Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study
• Efficacy of targeted therapy for advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
• Bronchiolar carcinoma: a case report with pulmonary function studies
• Nuclear metallothionein in oral squamous cell carcinoma: clinicopathological parameters and patient survival
• Jorge Lobo’s disease with malignant degeneration to squamous cell carcinoma: case report